By Associate Professor Yeh Chen Lee

Journal articles

Delahunty R; Nguyen L; Craig S; Creighton B; Ariyaratne D; Garsed DW; Christie E; Fereday S; Andrews L; Lewis A; Limb S; Pandey A; Hendley J; Traficante N; Carvajal N; Spurdle AB; Thompson B; Parsons MT; Beshay V; Volcheck M; Semple T; Lupat R; Doig K; Yu J; Chen XQ; Marsh A; Love C; Bilic S; Beilin M; Nichols CB; Greer C; Lee YC; Gerty S; Gill L; Newton E; Howard J; Williams R; Norris C; Stephens AN; Tutty E; Smyth C; O'connell S; Jobling T; Stewart CJR; Tan A; Fox SB; Pachter N; Li J; Ellul J; Mir Arnau G; Young MA; Gordon L; Forrest L; Harris M; Livingstone K; Hill J; Chenevix-Trench G; Cohen PA; Webb PM; Friedlander M; James P; Bowtell D; Alsop K, 2022, 'TRACEBACK: Testing of Historical Tubo-Ovarian Cancer Patients for Hereditary Risk Genes as a Cancer Prevention Strategy in Family Members', Journal of Clinical Oncology, 40, pp. 2036 - 2047, http://dx.doi.org/10.1200/JCO.21.02108

Woopen H; Sehouli J; Davis A; Lee YC; Cohen PA; Ferrero A; Gleeson N; Jhingran A; Kajimoto Y; Mayadev J; Barretina-Ginesta MP; Sundar S; Suzuki N; van Dorst E; Joly F, 2022, 'GCIG-Consensus guideline for Long-term survivorship in gynecologic Cancer: A position paper from the gynecologic cancer Intergroup (GCIG) symptom benefit committee', Cancer Treatment Reviews, 107, http://dx.doi.org/10.1016/j.ctrv.2022.102396

Krasovitsky M; Lee YC; Sim HW; Chawla T; Moore H; Moses D; Baker L; Mandel C; Kielar A; Hartery A; O'Malley M; Friedlander M; Oza AM; Wang L; Lheureux S; Wilson M, 2022, 'Interobserver and intraobserver variability of RECIST assessment in ovarian cancer', International Journal of Gynecological Cancer, 32, pp. 656 - 661, http://dx.doi.org/10.1136/ijgc-2021-003319

Farrell R; Burling M; Lee YC; Pather S; Robledo K; Mercieca-Bebber R; Stockler M, 2022, 'Clinical trial protocol for HyNOVA: Hyperthermic and normothermic intraperitoneal chemotherapy following interval cytoreductive surgery for stage iii epithelial ovarian, fallopian tube and primary peritoneal cancer (ANZGOG1901/2020)', Journal of Gynecologic Oncology, 33, http://dx.doi.org/10.3802/JGO.2022.33.E1

Lee YC; King MT; O'Connell RL; Lanceley A; Joly F; Hilpert F; Davis A; Roncolato FT; Okamoto A; Bryce J; Donnellan P; Oza AM; Avall-Lundqvist E; Berek JS; Ledermann JA; Berton D; Sehouli J; Feeney A; Kaminsky M-C; Diamante K; Stockler MR; Friedlander ML, 2022, 'Symptom Burden and Quality of Life With Chemotherapy for Recurrent Ovarian Cancer: The Gynecologic Cancer InterGroup-Symptom Benefit Study', Obstetrical & Gynecological Survey, 77, pp. 531 - 533, http://dx.doi.org/10.1097/ogx.0000000000001075

Obermair A; Beale P; Scott CL; Beshay V; Kichenadasse G; Simcock B; Nicklin J; Lee YC; Cohen P; Meniawy T, 2021, 'Insights into ovarian cancer care: Report from the Anzgog ovarian cancer webinar series 2020', Journal of Gynecologic Oncology, 32, http://dx.doi.org/10.3802/JGO.2021.32.E95

Werner B; Yuwono N; Duggan J; Liu D; David C; Srirangan S; Provan P; DeFazio A; Arora V; Farrell R; Lee YC; Warton K; Ford C, 2021, 'Cell-free DNA is abundant in ascites and represents a liquid biopsy of ovarian cancer', Gynecologic Oncology, 162, pp. 720 - 727, http://dx.doi.org/10.1016/j.ygyno.2021.06.028

Mileshkin LR; Moore KN; Barnes E; Gebski V; Narayan K; Bradshaw N; Lee YC; Diamante K; Fyles AW; Small W; Gaffney DK; Khaw P; Brooks S; Thompson JS; Huh WK; Carlson M; Mathews CA; Rischin D; Stockler MR; Monk BJ, 2021, 'Adjuvant chemotherapy following chemoradiation as primary treatment for locally advanced cervical cancer compared to chemoradiation alone: The randomized phase III OUTBACK Trial (ANZGOG 0902, RTOG 1174, NRG 0274).', JOURNAL OF CLINICAL ONCOLOGY, 39, http://dx.doi.org/10.1200/JCO.2021.39.15_suppl.LBA3

Antill Y; Kok PS; Robledo K; Yip S; Cummins M; Smith D; Spurdle A; Barnes E; Lee YC; Friedlander M; Baron-Hay S; Shannon C; Coward J; Beale P; Goss G; Meniawy T; Lombard J; Andrews J; Stockler MR; Mileshkin L, 2021, 'Clinical activity of durvalumab for patients with advanced mismatch repair-deficient and repair-proficient endometrial cancer. A nonrandomized phase 2 clinical trial', Journal for Immunotherapy of Cancer, 9, http://dx.doi.org/10.1136/jitc-2020-002255

Madariaga A; Garg S; Bruce JP; Thiryayi S; Mandilaras V; Rath P; Oza AM; Dhani NC; Cescon DW; Lee YC; Chen E; Wang L; Clarke B; Lheureux S, 2020, 'Biomarkers of outcome to weekly paclitaxel in epithelial ovarian cancer', Gynecologic Oncology, 159, pp. 539 - 545, http://dx.doi.org/10.1016/j.ygyno.2020.08.032

Lheureux S; Oaknin A; Garg S; Bruce JP; Madariaga A; Dhani NC; Bowering V; White J; Accardi S; Tan Q; Braunstein M; Karakasis K; Cirlan I; Pedersen S; Li T; Fariñas-Madrid L; Lee YC; Liu ZA; Pugh TJ; Oza AM, 2020, 'EVOLVE: A Multicenter Open-Label Single-Arm Clinical and Translational Phase II Trial of Cediranib plus Olaparib for Ovarian Cancer after PARP Inhibition Progression', Clinical Cancer Research, 26, pp. 4206 - 4215, http://dx.doi.org/10.1158/1078-0432.CCR-19-4121

Cusimano MC; Sajewycz K; Nelson M; Jivraj N; Lee YC; Bowering V; Oza A; Lheureux S; Ferguson SE, 2020, 'Supported self-management as a model for end-of-life care in the setting of malignant bowel obstruction: A qualitative study', Gynecologic Oncology, 157, pp. 745 - 753, http://dx.doi.org/10.1016/j.ygyno.2020.03.009

Liu SL; Lee YC; Jivraj N; Bowering V; Wang L; Bhat G; Madariaga A; Kasherman L; Nathwani K; Tesfu A; Lee S; Ferguson SE; Croke JM; O'Brien C; Lau J; Chawla T; Schlomovitz E; Oza AM; Lheureux S, 2020, 'Risk stratified multidisciplinary ambulatory management of malignant bowel obstruction (MAMBO) program for women with gynecological cancers: Preliminary results from a prospective single-center study.', Journal of Clinical Oncology, 38, pp. 6062 - 6062, http://dx.doi.org/10.1200/jco.2020.38.15_suppl.6062

Lee YC; Wang L; Kohn EC; Rubinstein L; Ivy SP; Harris PJ; Lheureux S, 2020, 'Evaluation of toxicities related to novel therapy in clinical trials for women with gynecologic cancer', Cancer, 126, pp. 2139 - 2145, http://dx.doi.org/10.1002/cncr.32783

Madariaga A; Garg S; Bruce J; Rath P; Mandilaras V; Thiryayi S; Oza AM; Dhani N; Lee YC; Clarke BA; Lheureux S, 2020, 'Biomarkers of outcome with weekly paclitaxel in platinum-resistant high-grade serous or endometrioid ovarian carcinoma', Gynecologic Oncology, 159, pp. 149 - 149, http://dx.doi.org/10.1016/j.ygyno.2020.05.207

Bhat G; Jivraj N; Oza AM; Dhani N; Lee YC; Madariaga A; Kasherman L; McMullen M; Liu S; Bowering V; Ferguson SE; Croke J; Lheureux S, 2020, 'Proactive inter-professional program to manage malignant bowel obstruction (MBO) in women with advanced gynecological cancer: Improving quality of care, education and awareness of malignant bowel obstruction among patients and health care providers', Gynecologic Oncology, 159, pp. 55 - 56, http://dx.doi.org/10.1016/j.ygyno.2020.06.116

Cusimano MC; Sajewycz K; Nelson M; Jivraj N; Bowering V; Lee YC; Lheureux S; Ferguson SE, 2020, 'Supported self-management as an innovative model of care for advanced gynecologic cancer patients with malignant bowel obstruction: A qualitative study', Gynecologic Oncology, 159, pp. 314 - 315, http://dx.doi.org/10.1016/j.ygyno.2020.05.568

Thomas R; Roy B; Maldonado F; Lee YCG, 2019, 'Management of Malignant Pleural Effusions-What Is New', SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE, 40, pp. 323 - 339, http://dx.doi.org/10.1055/s-0039-1698285

Bonilla L; Oza AM; Lheureux S; Saibil S; Chen S; Lee YC; Gray D; Colombo I; Madariaga A; Dhani NC; Bhat G; Bowering V; Garg S; Yokom D; Cyriac SL; Butler MO, 2019, 'Clinical outcome of sequential chemotherapy after immune checkpoint inhibitors in advanced ovarian cancer.', Journal of Clinical Oncology, 37, pp. 5580 - 5580, http://dx.doi.org/10.1200/jco.2019.37.15_suppl.5580

Lheureux S; Oaknin A; Garg S; Bruce J; Dhani NC; Madariaga A; Bonilla L; Lee YC; Colombo I; Bhat G; Bowering V; White J; Accardi S; Tan S; Braunstein M; Karakasis K; Liu ZA; Pugh TJ; Oza AM, 2019, 'Evolve: A post PARP inhibitor clinical translational phase II trial of cediranib-olaparib in ovarian cancer—A Princess Margaret Consortium – GCIG Phase II Trial.', Journal of Clinical Oncology, 37, pp. 5521 - 5521, http://dx.doi.org/10.1200/jco.2019.37.15_suppl.5521

Bhat G; Madariaga A; Bonilla L; Lee YC; Dhani NC; Jivraj N; Chawla T; Buchanan S; Ferguson S; O'Brien C; Dhar P; Shlomovitz E; Lau J; Mulumba S; Karakasis K; Chllamma M; Oza AM; Lheureux S, 2019, 'Implementation of malignant bowel obstruction multidisciplinary case conferences (MCCs) to improve clinical decision making in malignant bowel obstruction (MBO) in gynecologic oncology.', Journal of Clinical Oncology, 37, pp. e18322 - e18322, http://dx.doi.org/10.1200/jco.2019.37.15_suppl.e18322

Lee YC; Jivraj N; Wang L; Chawla T; Lau J; Croke J; Allard JP; Stuart-McEwan T; Nathwani K; Bowering V; Karakasis K; O’Brien C; Shlomovitz E; Ferguson SE; Buchanan S; Ng P; Cyriac S; Tinker L; Dhani N; Oza AM; Lheureux S, 2019, 'Optimizing the care of malignant bowel obstruction in patients with advanced gynecologic cancer', Journal of Oncology Practice, 15, pp. e1066 - e1075, http://dx.doi.org/10.1200/JOP.18.00793

Lee YC; Davis A, 2019, 'To treat or not to treat', JNCI Cancer Spectrum, 3, pp. pkz023, http://dx.doi.org/10.1093/jncics/pkz023

Kwan B, 2018, 'Aggressive versus symptom-guided drainage of malignant pleural effusion via indwelling pleural catheters (AMPLE-2): an open-label randomised trial', The Lancet Respiratory Medicine, 6, pp. 671 - 680, http://dx.doi.org/10.1016/S2213-2600(18)30288-1

Cyriac SL; Wilson MK; Bowering VL; Hunt W; Gutierrez D; Lee YC; Colombo I; Bonilla L; Speers V; Ghai S; Dhani NC; Butler MO; Oza AM; Lheureux S, 2018, 'Prospective assessment of tumor biopsies as part of clinical trials: Patients’ (pts) perspectives.', Journal of Clinical Oncology, 36, pp. 2539 - 2539, http://dx.doi.org/10.1200/jco.2018.36.15_suppl.2539

Lee YC; Wang L; Kohn EC; Rubinstein L; Ivy SP; Harris P; Lheureux S, 2018, 'Toxicity profile of patients with gynecological cancers (Gyne) enrolled in phase I trials.', Journal of Clinical Oncology, 36, pp. 5572 - 5572, http://dx.doi.org/10.1200/jco.2018.36.15_suppl.5572

Lee YC; Jivraj N; O'brien C; Chawla T; Shlomovitz E; Buchanan S; Lau J; Croke J; Allard JP; Dhar P; Laframboise S; Ferguson SE; Dhani N; Butler M; Ng P; Stuart-Mcewan T; Savage P; Tinker L; Oza AM; Lheureux S, 2018, 'Malignant Bowel Obstruction in Advanced Gynecologic Cancers: An Updated Review from a Multidisciplinary Perspective', Obstetrics and Gynecology International, 2018, pp. 1867238, http://dx.doi.org/10.1155/2018/1867238

Thomas R; Fysh ETH; Smith NA; Lee P; Kwan BCH; Yap E; Horwood FC; Piccolo F; Lam DCL; Garske LA; Shrestha R; Kosky C; Read CA; Murray K; Lee YCG, 2017, 'Effect of an indwelling pleural catheter vs talc pleurodesis on hospitalization days in patients with malignant pleural effusion: The AMPLE randomized clinical trial', JAMA Journal of the American Medical Association, 318, pp. 1903 - 1912, http://dx.doi.org/10.1001/jama.2017.17426

Lee YC; Jivraj N; O'Brien C; Lau J; Chawla T; Shlomovitz E; Buchanan S; Croke J; Allard JP; Dhar P; Laframboise S; Ferguson SE; Dhani NC; Butler MO; Ng P; Stuart-McEwan T; Savage P; Tinker LM; Oza AM; Lheureux S, 2017, 'Novel malignant bowel obstruction (MBO) management program for women with advanced gynecological cancer.', Journal of Clinical Oncology, 35, pp. 158 - 158, http://dx.doi.org/10.1200/jco.2017.35.31_suppl.158

Lee YC; Bressel M; Grant P; Russell P; Smith C; Picken S; Camm S; Kiely BE; Milne RL; McLachlan SA; Hickey M; Friedlander ML; Hopper JL; Phillips KA, 2017, 'Improved quality of risk-reducing salpingo-oophorectomy in Australasian women at high risk of pelvic serous cancer', Familial Cancer, 16, pp. 461 - 469, http://dx.doi.org/10.1007/s10689-017-9977-x

Lee YC; Milne RL; Lheureux S; Friedlander M; McLachlan SA; Martin KL; Bernardini MQ; Smith C; Picken S; Nesci S; Hopper JL; Phillips KA, 2017, 'Risk of uterine cancer for BRCA1 and BRCA2 mutation carriers', European Journal of Cancer, 84, pp. 114 - 120, http://dx.doi.org/10.1016/j.ejca.2017.07.004

Lee YC; Kroon R; Koczwara B; Haines I; Francis K; Millward M; Kefford R; Olver I; Mileshkin L, 2017, 'Survey of practices around pharmaceutical company funding for continuing professional development among medical oncologists and trainees in Australia', Internal Medicine Journal, 47, pp. 888 - 893, http://dx.doi.org/10.1111/imj.13482

Lee YC; Lheureux S; Jivraj N; O'Brien C; Laframboise S; Tinker LM; Patel T; Stuart-McEwan T; Savage P; Easson AM; Croke J; Lau J; Shlomovitz E; Chawla T; Allard J; Buchanan S; Ng P; Karakasis K; Oza AM, 2017, 'Risk-stratified multidisciplinary ambulatory management of malignant bowel obstruction (MAMBO) program for women with advanced gynecological cancer.', Journal of Clinical Oncology, 35, pp. e18024 - e18024, http://dx.doi.org/10.1200/jco.2017.35.15_suppl.e18024

Williamson JP; Twaddell SH; Lee YCG; Salamonsen M; Hew M; Fielding D; Nguyen P; Steinfort D; Hopkins P; Smith N; Grainge C, 2017, 'Thoracic ultrasound recognition of competence: A position paper of the Thoracic Society of Australia and New Zealand', Respirology, 22, pp. 405 - 408, http://dx.doi.org/10.1111/resp.12977

Lee YC; Lheureux S; Oza AM, 2017, 'Treatment strategies for endometrial cancer: Current practice and perspective', Current Opinion in Obstetrics and Gynecology, 29, pp. 47 - 58, http://dx.doi.org/10.1097/GCO.0000000000000338

Brown SGA; Ball EL; Perrin K; Read CA; Asha SE; Beasley R; Egerton-Warburton D; Jones PG; Keijzers G; Kinnear FB; Kwan BCH; Lee YCG; Smith JA; Summers QA; Simpson G; Lee YC, 2016, 'Study protocol for a randomised controlled trial of invasive versus conservative management of primary spontaneous pneumothorax', BMJ Open, 6, pp. e011826, http://dx.doi.org/10.1136/BMJOPEN-2016-011826

Lee YC; Michael M; Zalcberg JR, 2015, 'An overview of experimental and investigational multikinase inhibitors for the treatment of metastatic colorectal cancer', Expert Opinion on Investigational Drugs, 24, pp. 1307 - 1320, http://dx.doi.org/10.1517/13543784.2015.1070483

Birnie KA; Yip YY; Ng DCH; Kirschner MB; Reid G; Prêle CM; Musk AW; Lee YCG; Thompson PJ; Mutsaers SE; Badrian B, 2015, 'Loss of miR-223 and JNK signaling contribute to elevated stathmin in malignant pleural mesothelioma', Molecular Cancer Research, 13, pp. 1106 - 1118, http://dx.doi.org/10.1158/1541-7786.MCR-14-0442

Fysh ETH; Thomas R; Read CA; Lam BCH; Yap E; Horwood FC; Lee P; Piccolo F; Shrestha R; Garske LA; Lam DCL; Rosenstengel A; Bint M; Murray K; Smith NA; Lee YCG, 2014, 'Protocol of the Australasian Malignant Pleural Effusion (AMPLE) trial: a multicentre randomised study comparing indwelling pleural catheter versus talc pleurodesis', BMJ OPEN, 4, http://dx.doi.org/10.1136/bmjopen-2014-006757

Fysh ETH; Tremblay A; Feller-Kopman D; Mishra EK; Slade M; Garske L; Clive AO; Lamb C; Boshuizen R; Ng BJ; Rosenstengel AW; Yarmus L; Rahman NM; Maskell NA; Lee YCG, 2013, 'Clinical Outcomes of Indwelling Pleural Catheter-Related Pleural Infections An International Multicenter Study', CHEST, 144, pp. 1597 - 1602, http://dx.doi.org/10.1378/chest.12-3103

Oh SY; Griffiths D; John T; Lee YC; Yu LM; McCarthy N; Heath PT; Crook D; Ramsay M; Richard Moxon E; Pollard AJ, 2008, 'School-aged children: A reservoir for continued circulation of Haemophilus influenzae type b in the United Kingdom', Journal of Infectious Diseases, 197, pp. 1275 - 1281, http://dx.doi.org/10.1086/586716

Yeh CL; Kelly DF; Yu LM; Slack MPE; Booy R; Heath PT; Siegrist CA; Moxon RE; Pollard AJ, 2008, 'Haemophilus influenzae type b vaccine failure in children is associated with inadequate production of high-quality antibody', Clinical Infectious Diseases, 46, pp. 186 - 192, http://dx.doi.org/10.1086/524668

Lee YC; Newport MJ; Goetghebuer T; Siegrist CA; Weiss HA; Pollard AJ; Marchant A, 2006, 'Influence of genetic and environmental factors on the immunogenicity of Hib vaccine in Gambian twins', Vaccine, 24, pp. 5335 - 5340, http://dx.doi.org/10.1016/j.vaccine.2006.04.021

Johnson NG; Ruggeberg JU; Balfour GF; Lee YC; Liddy H; Irving D; Sheldon J; Slack MPE; Pollard AJ; Heath PT, 2006, 'Haemophilus influenzae type b reemergence after combination immunization', Emerging Infectious Diseases, 12, pp. 937 - 941, http://dx.doi.org/10.3201/eid1206.051451

Conference Papers

Colombo N; Harano K; Hudson E; Galli F; Antill Y; Choi CH; Rabaglio M; Marmé F; Petru E; Lai C-H; Biagioli E; Fariñas-Madrid L; Takehara K; Allan K; Lee YC; Piovano E; Zamagni C; Tasca G; Ferrero A; Barretina-Ginesta M-P, 2024, '546 AtTEnd/ENGOT-EN7: phase III double-blind randomized placebo controlled trial of atezolizumab in combination with carboplatin and paclitaxel in women with advanced/recurrent endometrial carcinoma', in Oral Sessions, BMJ Publishing Group Ltd, pp. A21.1 - A21, presented at ESGO 2024 Congress Abstracts, http://dx.doi.org/10.1136/ijgc-2024-esgo.27

Buchanan D; Joo J-HE; Mahmood K; Georgeson P; Walker R; Robledo K; Cummins M; Spurdle AB; Smith D; Clendenning M; Como J; Preston S; Yip S; Andrews J; Kok P-S; Lee YC; Stockler M; Mileshkin L; Antill Y, 2024, '713 The impact of cause of mismatch repair deficiency and other molecular markers on clinical outcomes with the use of durvalumab in advanced endometrial cancer in the phase 2 PHAEDRA trial (ANZGOG1601)', in Poster and E-Posters, BMJ Publishing Group Ltd, pp. A504.1 - A504, presented at ESGO 2024 Congress Abstracts, http://dx.doi.org/10.1136/ijgc-2024-esgo.988

Nishio S; Pardo B; Hudson E; Rulli E; Antill Y; Lee C; Rabaglio M; Heitz F; Leitner K; Lai C-H; Uggeri S; Manso L; Harano K; Allan K; Lee YC; Tognon G; Canova S; Petrella MC; Gadducci A; Colombo N, 2024, 'Phase III double-blind randomized placebo controlled trial of atezolizumab in combination with carboplatin and paclitaxel in women with advanced/recurrent endometrial carcinoma: the Asian cohort of AtTEnd/ENGOT-EN7 trial', in INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, ELSEVIER, pp. A20 - A21, http://dx.doi.org/10.1136/ijgc-2024-ESGO.26

Oaknin A; Lorusso D; Pietzner K; Lee J-Y; Cibula D; Lee YC; Schilder R; Auranen A; Gao B; Tan D; Oza A; Miller R; Salutari V; Tasca G; O’Malley D; Monk B; Pothuri B; Lu L; Berman C; Borgman A; Wendel Naumann R, 2024, 'TP010/#1537  Efficacy and safety of luveltamab tazevibulin in patients with recurrent platinum-resistant ovarian cancer: the reframe-01 (GOG-3086, ENGOT-79ov, and APGOT-OV9) phase 2/3 study', in E-Poster Viewing Abstracts – Trials in Progress, BMJ Publishing Group Ltd, pp. A351.1 - A351, presented at IGCS 2024 Annual Meeting Abstracts, http://dx.doi.org/10.1136/ijgc-2024-igcs.612

Werner B; Powell E; Duggan J; Lee YC; Athavale R; Dean M; Warton K; Ford C, 2023, 'Cell-free DNA from ascites identifies clinically relevant variants and tumour evolution in a cohort of patients with advanced ovarian cancer', in INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, BMJ PUBLISHING GROUP, pp. A32 - A33, http://dx.doi.org/10.1136/ijgc-2023-IGCS.47

Au-Yeung G; Bressel M; Prall O; Opar P; Andrews J; Mongta S; Lee YC; Gao B; Meniawy T; Baron-Hay S; Black A; Kichenadasse G; Ananda S; Fox P; Bowtell D; Mileshkin L, 2023, 'PO003/#269  Ignite: a phase II signal-seeking trial of adavosertib targeting recurrent high grade serous ovarian cancer with cyclin E1 over-expression with and without gene amplification', in Plenary 01: Oral Abstract Presentations, BMJ Publishing Group Ltd, pp. A2 - A3, presented at IGCS 2023 Annual Meeting Abstracts, http://dx.doi.org/10.1136/ijgc-2023-igcs.3

Back to profile page